{"title":"早期乳腺癌，egfr突变的非小细胞肺癌和高风险黑色素瘤:2023年ASCO年会重点关注高级从业者","authors":"Lisa Kottschade, APRN, MSN, CNP, FAPO","doi":"10.6004/jadpro.2023.14.6.10","DOIUrl":null,"url":null,"abstract":"Lisa Kottschade, APRN, MSN, CNP, FAPO, of Mayo Clinic, discusses encouraging results of a trial examining adjuvant ribociclib plus estrogen therapy in patients with stage II or III HR+/HER2− early breast cancer. She also discusses the use of the novel mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma. Finally, she analyzes the overall survival data reported in the ADAURA trial, which demonstrated a statistically significant disease-free and overall survival benefit for patients with EGFR-mutated stage IB to IIIA non–small cell lung cancer.","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"33 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early-Stage Breast Cancer, EGFR-Mutated NSCLC, and High-Risk Melanoma: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner\",\"authors\":\"Lisa Kottschade, APRN, MSN, CNP, FAPO\",\"doi\":\"10.6004/jadpro.2023.14.6.10\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lisa Kottschade, APRN, MSN, CNP, FAPO, of Mayo Clinic, discusses encouraging results of a trial examining adjuvant ribociclib plus estrogen therapy in patients with stage II or III HR+/HER2− early breast cancer. She also discusses the use of the novel mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma. Finally, she analyzes the overall survival data reported in the ADAURA trial, which demonstrated a statistically significant disease-free and overall survival benefit for patients with EGFR-mutated stage IB to IIIA non–small cell lung cancer.\",\"PeriodicalId\":17176,\"journal\":{\"name\":\"Journal of the Advanced Practitioner in Oncology\",\"volume\":\"33 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Advanced Practitioner in Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2023.14.6.10\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.6.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Early-Stage Breast Cancer, EGFR-Mutated NSCLC, and High-Risk Melanoma: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner
Lisa Kottschade, APRN, MSN, CNP, FAPO, of Mayo Clinic, discusses encouraging results of a trial examining adjuvant ribociclib plus estrogen therapy in patients with stage II or III HR+/HER2− early breast cancer. She also discusses the use of the novel mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma. Finally, she analyzes the overall survival data reported in the ADAURA trial, which demonstrated a statistically significant disease-free and overall survival benefit for patients with EGFR-mutated stage IB to IIIA non–small cell lung cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
